Illustration of the Added Value of 18F-DOPA PET to Multimodal MRI to Distinguish Low- and High-Grade Gliomas.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Jul 2021
01 Jul 2021
Historique:
pubmed:
13
2
2021
medline:
22
6
2021
entrez:
12
2
2021
Statut:
ppublish
Résumé
18F-DOPA PET-MRI was performed on a 38-year-old man referred for complementary imaging after a brain tumor was discovered, according to EANM/RANO recommendations. We performed a simultaneous PET with 3-T brain MRI, which revealed 2 high 18F-DOPA uptakes, with no multimodal MRI sign of aggressiveness. An awake surgery was performed and found a grade III anaplastic astrocytoma IDH1-R132L mutant, according to the 2016 WHO classification. This was probably the aggressive transition of a grade II diffuse astrocytoma. This case illustrates the added value of 18F-DOPA PET to multimodal MRI to distinguish low- and high-grade gliomas.
Identifiants
pubmed: 33577196
doi: 10.1097/RLU.0000000000003507
pii: 00003072-202107000-00025
doi:
Substances chimiques
fluorodopa F 18
2C598205QX
Dihydroxyphenylalanine
63-84-3
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e353-e354Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest disclosure: none declared.
Références
Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [ 18 F]FDG: version 1.0. Eur J Nucl Med Mol Imaging . 2019;46:540–557.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol . 2016;131:803–820.
Fueger BJ, Czernin J, Cloughesy T, et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med . 2010;51:1532–1538.
Patel CB, Fazzari E, Chakhoyan A, et al. 18 F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. J Neurooncol . 2018;139:399–409.
Nioche C, Soret M, Gontier E, et al. Evaluation of quantitative criteria for glioma grading with static and dynamic 18 F-FDopa PET/CT. Clin Nucl Med . 2013;38:81–87.
Pafundi DH, Laack NN, Youland RS, et al. Biopsy validation of 18 F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol . 2013;15:1058–1067.
Rossi Espagnet MC, Romano A, Mancuso V, et al. Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET. Br J Radiol . 2016;89:20160476.
Bund C, Heimburger C, Imperiale A, et al. FDOPA PET-CT of nonenhancing brain tumors. Clin Nucl Med . 2017;42:250–257.